Mérieux Equity Partners
Growth equityParis · Seed–Late Stage
Investment thesis
Mérieux Partners leverages deep expertise and established networks within healthcare to identify and support companies developing innovative medical solutions and transformative health products or services. The firm pursues a dual-strategy approach through dedicated Innovation and Buyout platforms, enabling investment across the healthcare sector from early-stage ventures through mature companies.
Source: firm website, verified Jul 21, 2026.
What they invest in
from 1 of 11 portfolio companiesBiotech ×1Deep Tech ×1Medical Devices ×1
Investments · 11 tracked
founders shown can be your intro pathBroken String Bio develops genome-wide on- and off-target analysis software and sequencing technology for gene editing research and development. The platform serves biotech and pharmaceutical companies conducting gene editing discovery, optimization, and characterization across diverse cell types and nuclease systems.
BiotechDeep TechMedical Devices
Frequently asked questions
- What stage does Mérieux Equity Partners invest at?
- Mérieux Equity Partners invests at the Seed, Series A, Series B, Growth, Late Stage stages.
- What is Mérieux Equity Partners's typical check size?
- Mérieux Equity Partners typically writes checks of $3.3M – $86.5M.
- What sectors does Mérieux Equity Partners focus on?
- Mérieux Equity Partners focuses on Biotech, Healthtech, Medical Devices.
- Where is Mérieux Equity Partners located?
- Mérieux Equity Partners is headquartered in Paris, FR.
- Does Mérieux Equity Partners lead rounds?
- Yes, Mérieux Equity Partners leads investment rounds.
Images
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
USVP is a venture capital firm with over 40 years of history across four generations of technology investing. The firm has deployed $4.7B across 542 companies, generating 97 IPOs, and combines 150 years of combined operating experience with deep expertise in enterprise software, security, consumer technology, and healthcare.
A venture capital firm that supports founders developing transformative solutions across interconnected systems, with a particular focus on leveraging artificial intelligence and related technologies to advance health and human flourishing.